Wednesday, December 4th, 2019
MolMed is a biotechnology company focused on research, development and manufacturing of innovative therapies to treat cancer and rare genetic diseases. MolMed has developed a robust and scalable process for the industrial scale production of both LV and RV vectors for use in gene-modified cell therapy using the iCELLis® bioreactor platforms. In this webinar, Molmed will present the development and optimization of their LV and RV vector production processes.
Don’t miss this detailed case study from Giuliana Vallanti, PhD at MolMed and Clive Glover, PhD at Pall Biotech followed by a live Q&A